Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IDEAYA Biosciences Inc IDYA

Healthcare Biotechnology
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with... see more

Bullboard (NDAQ:IDYA)

View:
User Avatar Image
(280)
•••
  • whytestocksX
Post by whytestockson Nov 13, 2024 2:15am

(IDYA) Investment Analysis

NEWS: $IDYA (IDYA) Investment Analysis2024-11-13 01:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and ...more  
78
User Avatar Image
(280)
•••
  • whytestocksX
Post by whytestockson Jul 10, 2024 6:00pm

Outperform Recommendation Issued On IDYA By RBC Capital

News; $IDYA Outperform Recommendation Issued On IDYA By RBC Capital2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous ...more  
70
User Avatar Image
(280)
•••
  • whytestocksX
Post by whytestockson Jul 08, 2024 10:47am

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expans

BREAKING NEWS: $IDYA IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung CancerIDEAYA ...more  
37
User Avatar Image
(280)
•••
  • whytestocksX
Post by whytestockson Jul 05, 2024 4:15pm

IDEAYA Announces Investor Webcast to Report Clinical Data Up

Just In: $IDYA IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024IDEAYA ...more  
51
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Jan 26, 2022 8:12am

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$IDYA $NKTR $MGNX $CTMX $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,650 deaths every year as per an estimate by the American Cancer ...more  
112
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities